Completed
A randomized prospective open-label study of switching to raltegravir based antiretroviral therapy (ART) compared to maintaining ritonavir boosted protease inhibitor-based ART on liver fibrosis progression in HIV-HCV co-infected individuals.
Learn MoreCompleted
Impact of HIV infection and antiretroviral therapy on mucosal and systemic memory CD4 T cells
Learn MoreCompleted
A randomized, double blind, phase IIB study testing the efficacy and safety of AGS-004 on host control of HIV replication during analytical treatment interruption: Trial results
Learn MoreReporting
Predictive value of inflammatory biomarkers in untreated HIV disease progression, and their response to initiation of antiretroviral therapy
Learn MoreCompleted
PCIRN evaluation of pandemic H1N1 (2009) influenza vaccine in adults with human immunodeficiency virus infection: Trial results
Learn MoreReporting
A randomized clinical trial evaluating the role of contingent reinforcement in the engagement and retention of Drug Users in HAART programs: a substudy of CTN 244
Learn MoreReporting
A study of host and viral factors associated with disease progression in long term HIV infected subjects
Learn MoreCompleted
Chloroquine as a modulator of T cell immune activation to improve CD4 recovery in HIV-infected participants receiving antiretroviral therapy: A proof-of-concept study
Learn MoreCompleted
Seek and Treat for Optimal outcomes and Prevention in HIV& AIDS in IDU
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
